Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 25;10(6):1309.
doi: 10.3390/cells10061309.

Neuroprotective Natural Products for Alzheimer's Disease

Affiliations
Review

Neuroprotective Natural Products for Alzheimer's Disease

Xin Chen et al. Cells. .

Abstract

Alzheimer's disease (AD) is the number one neurovegetative disease, but its treatment options are relatively few and ineffective. In efforts to discover new strategies for AD therapy, natural products have aroused interest in the research community and in the pharmaceutical industry for their neuroprotective activity, targeting different pathological mechanisms associated with AD. A wide variety of natural products from different origins have been evaluated preclinically and clinically for their neuroprotective mechanisms in preventing and attenuating the multifactorial pathologies of AD. This review mainly focuses on the possible neuroprotective mechanisms from natural products that may be beneficial in AD treatment and the natural product mixtures or extracts from different sources that have demonstrated neuroprotective activity in preclinical and/or clinical studies. It is believed that natural product mixtures or extracts containing multiple bioactive compounds that can work additively or synergistically to exhibit multiple neuroprotective mechanisms might be an effective approach in AD drug discovery.

Keywords: Alzheimer’s disease (AD); amyloid β peptide (Aβ); anti-neuroinflammatory; antioxidant; natural products; neurodegenerative; neurofibrillary tangles (NFTs); neuroprotective.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Neuroprotective effects from natural products for AD.

References

    1. Hippius H., Neundorfer G. The discovery of Alzheimer′s disease. Dialogues Clin. Neurosci. 2003;5:101–108. - PMC - PubMed
    1. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement. 2020 doi: 10.1002/alz.12068. - DOI - PubMed
    1. Kawas C.H., Corrada M.M. Alzheimer’s and dementia in the oldest-old: A century of challenges. Curr. Alzheimer Res. 2006;3:411–419. doi: 10.2174/156720506779025233. - DOI - PMC - PubMed
    1. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–1356. doi: 10.1001/jama.1997.03550160069041. - DOI - PubMed
    1. Hebert L.E., Weuve J., Scherr P.A., Evans D.A. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80:1778–1783. doi: 10.1212/WNL.0b013e31828726f5. - DOI - PMC - PubMed